BRPI0419067A - método para aumento da cognição utilizando ziprasidona - Google Patents
método para aumento da cognição utilizando ziprasidonaInfo
- Publication number
- BRPI0419067A BRPI0419067A BRPI0419067-0A BRPI0419067A BRPI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A BR PI0419067 A BRPI0419067 A BR PI0419067A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- ziprasidone
- formula
- compound
- human
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 5
- 229960000607 ziprasidone Drugs 0.000 title abstract 5
- 230000019771 cognition Effects 0.000 title abstract 3
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- 206010003805 Autism Diseases 0.000 abstract 2
- 208000020706 Autistic disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 208000036626 Mental retardation Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000009329 sexual behaviour Effects 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010019191 Head banging Diseases 0.000 abstract 1
- 206010022524 Intentional self-injury Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000005560 Self Mutilation Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 231100000867 compulsive behavior Toxicity 0.000 abstract 1
- -1 piperazinyl heterocyclic compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000013623 stereotypic movement disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47137903P | 2003-05-16 | 2003-05-16 | |
| PCT/IB2004/001600 WO2004100956A1 (en) | 2003-05-16 | 2004-05-05 | Method for enhancing cognition using ziprasidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0419067A true BRPI0419067A (pt) | 2007-12-11 |
Family
ID=33452442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0419067-0A BRPI0419067A (pt) | 2003-05-16 | 2004-05-05 | método para aumento da cognição utilizando ziprasidona |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050014764A1 (enExample) |
| EP (1) | EP1626722A1 (enExample) |
| JP (1) | JP2006528236A (enExample) |
| AR (1) | AR044337A1 (enExample) |
| BR (1) | BRPI0419067A (enExample) |
| CA (2) | CA2625837A1 (enExample) |
| MX (1) | MXPA05012325A (enExample) |
| TW (1) | TW200507847A (enExample) |
| WO (1) | WO2004100956A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003007956A1 (en) | 2001-07-20 | 2003-01-30 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
| ES2639579T3 (es) | 2003-04-29 | 2017-10-27 | Orexigen Therapeutics, Inc. | Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión |
| MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| JP5180092B2 (ja) | 2005-11-22 | 2013-04-10 | オレキシジェン・セラピューティクス・インコーポレーテッド | インスリン感受性を増すための組成物および方法 |
| BRPI0707223A2 (pt) * | 2006-01-27 | 2011-04-26 | Pfizer Prod Inc | compostos de derivados de aminoftalazina |
| EP1988077A4 (en) | 2006-02-23 | 2009-09-02 | Shionogi & Co | NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| ATE545416T1 (de) * | 2006-10-12 | 2012-03-15 | Xenon Pharmaceuticals Inc | Verwendung von spiro-oxindol-verbindungen als therapeutika |
| JP2010522690A (ja) * | 2006-10-12 | 2010-07-08 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 三環式スピロオキシインドール誘導体および治療薬としてのその使用 |
| CL2007002953A1 (es) * | 2006-10-12 | 2008-02-01 | Xenon Pharmaceuticals Inc | Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia. |
| CN101573103A (zh) | 2006-11-09 | 2009-11-04 | 奥雷西根治疗公司 | 用于施用重量减轻药物的单位剂量包装和方法 |
| MX2009014216A (es) * | 2007-06-29 | 2010-07-05 | Univ Emory | Antagonistas del receptor nmda para neuroproteccion. |
| CA2722776A1 (en) * | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| HRP20150882T1 (hr) | 2008-10-17 | 2015-09-25 | Xenon Pharmaceuticals Inc. | Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva |
| WO2010045197A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| MY165579A (en) * | 2009-10-14 | 2018-04-05 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| KR20120124423A (ko) | 2010-01-11 | 2012-11-13 | 오렉시젠 세러퓨틱스 인크. | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 |
| JP2013521232A (ja) | 2010-02-26 | 2013-06-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 局所投与のためのスピロオキシインドール化合物の医薬組成物および治療剤としてのその使用 |
| CA2799154A1 (en) | 2010-05-12 | 2011-11-17 | Abbvie Inc. | Indazole inhibitors of kinase |
| RS67076B1 (sr) | 2012-06-06 | 2025-08-29 | Nalpropion Pharmaceuticals Llc | Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| WO2016191316A1 (en) * | 2015-05-22 | 2016-12-01 | Stem Cell Theranostics, Inc. | Modulation of drug-induced cardiotoxicity |
| JP2025510646A (ja) | 2022-03-14 | 2025-04-15 | スラップ ファーマシューティカルズ エルエルシー | 多環式化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US6110918A (en) * | 1996-05-07 | 2000-08-29 | Pfizer Inc | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| AU3329500A (en) * | 1999-03-30 | 2000-10-23 | Lion Corporation | Hairdye composition of single preparation type containing an oxidase |
| JP2002541098A (ja) * | 1999-04-06 | 2002-12-03 | セプラコア インコーポレーテッド | ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物 |
-
2004
- 2004-05-05 EP EP04731234A patent/EP1626722A1/en not_active Withdrawn
- 2004-05-05 WO PCT/IB2004/001600 patent/WO2004100956A1/en not_active Ceased
- 2004-05-05 JP JP2006530660A patent/JP2006528236A/ja active Pending
- 2004-05-05 BR BRPI0419067-0A patent/BRPI0419067A/pt not_active IP Right Cessation
- 2004-05-05 CA CA002625837A patent/CA2625837A1/en not_active Abandoned
- 2004-05-05 MX MXPA05012325A patent/MXPA05012325A/es unknown
- 2004-05-05 CA CA002525323A patent/CA2525323A1/en not_active Abandoned
- 2004-05-14 AR ARP040101652A patent/AR044337A1/es unknown
- 2004-05-14 TW TW093113727A patent/TW200507847A/zh unknown
- 2004-05-14 US US10/846,797 patent/US20050014764A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/110,522 patent/US20080269246A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05012325A (es) | 2006-01-30 |
| JP2006528236A (ja) | 2006-12-14 |
| TW200507847A (en) | 2005-03-01 |
| CA2525323A1 (en) | 2004-11-25 |
| US20080269246A1 (en) | 2008-10-30 |
| WO2004100956A1 (en) | 2004-11-25 |
| US20050014764A1 (en) | 2005-01-20 |
| EP1626722A1 (en) | 2006-02-22 |
| AR044337A1 (es) | 2005-09-07 |
| CA2625837A1 (en) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0419067A (pt) | método para aumento da cognição utilizando ziprasidona | |
| TN2009000242A1 (en) | Sulfonyl-phenyl-2h-[1,2,4]oxodiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals | |
| TNSN08145A1 (en) | Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals | |
| BRPI0518798A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodos para tratar diabete tipo ii e para tratar uma condiÇço ou distérbio | |
| MA34922B1 (fr) | Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques | |
| BR0312999A (pt) | Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente | |
| BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| EA200900940A1 (ru) | Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное | |
| WO2007095050A3 (en) | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | |
| BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
| BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
| MA32323B1 (fr) | Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques | |
| BRPI0410235A (pt) | inibição de pde4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento | |
| MA32108B1 (fr) | Derives d'indazole | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| MA30592B1 (fr) | Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques | |
| BRPI0411098A (pt) | benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos | |
| BR0011403A (pt) | Processos para a purificação e para a preparação de ácido acrìlico ou ácido metacrìlico | |
| EA200800303A1 (ru) | Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами | |
| BRPI0713381A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de uma doença | |
| BRPI0410222A (pt) | tratamento de distúrbios bipolares e sintomas associados | |
| BRPI0509512A (pt) | método de tratar esquizofrenia e/ou anormalidades glicorregulatórias | |
| TW200508210A (en) | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
| BRPI0514419A (pt) | amidas do ácido tienopirrol carboxìlico substituìdas, amidas do ácido pirrolotiazol carboxìlico, e análogos relacionados como inibidores de caseìna cinase iépsilon, bem como composição farmacêutica e processo para a preparação dos mesmos | |
| TW200621732A (en) | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 3A. E 6A. ANUIDADES. |
|
| B08J | Incorrect entry in the gazette republished [chapter 8.10 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2082 DE 30/11/2010. TEXTO CORRETO: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AOS DESPACHOS PUBLICADOS NA RPI 2082 DE 30/11/2010 E RPI 2090 DE 25/01/2011. |